Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 464-468

  Togashi, Yosuke ^a   Masago, Katsuhiro ^a   Hamatani, Yasuhiro ^a   Sakamori, Yuichi ^a   Nagai, Hiroki ^a   Kim, Young Hak ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor gene mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Gefitinib; Interstitial lung disease; Leptomeningeal metastases; Rechallenge

Indexed keywords

BETAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PREDNISOLONE;

AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CONSCIOUSNESS DISORDER; CORTICOSTEROID THERAPY; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; GENE MUTATION; HEADACHE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LEPTOMENINGEAL METASTASIS; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; RETREATMENT; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84863778941     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.013     Document Type: Article

References (31)

1. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
2. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
3. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
4. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
5. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. North-East Japan Study G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
8. Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006, 5:443-452.
9. Lombardi G., Zustovich F., Farina P., Della Puppa A., Manara R., Cecchin D., et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist 2011, 16:1175-1188.
10. Yi H.G., Kim H.J., Kim Y.J., Han S.W., Oh D.Y., Lee S.H., et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009, 65:80-84.
11. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8:303-306.
12. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10:461-466.
13. Inoue A., Saijo Y., Maemondo M., Gomi K., Tokue Y., Kimura Y., et al. Severe acute interstitial pneumonia and gefitinib. The Lancet 2003, 361:137-139.
14. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177:1348-1357.
15. Hotta K., Kiura K., Takigawa N., Yoshioka H., Harita S., Kuyama S., et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama lung cancer study group experience. J Thorac Oncol. 2010, 179-184.
16. Ter Heine R., van den Bosch R.T., Schaefer-Prokop C.M., Lankheet N.A., Beijnen J.H., Staaks G.H., et al. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer 2011.
17. Takamochi K., Suzuki K., Bashar A.H., Yajima K., Mochizuki T., Itaya T., et al. Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J Med Case Reports 2007, 1:138.
18. Suzuki M., Asahina H., Konishi J., Yamazaki K., Nishimura M. Recurrent gefitinib-induced interstitial lung disease. Intern Med 2008, 533-536.
19. Fukui T., Otani S., Hataishi R., Jiang S.X., Nishii Y., Igawa S., et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010, 65:803-806.
20. Chang S.C., Chang C.Y., Chen C.Y., Yu C.J. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 2010, 1105-1106.
21. Takeda M., Okamoto I., Makimura C., Fukuoka M., Nakagawa K. Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol 2010, 1103-1104.
22. Tian Q., Chen L.A. Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease. Case Rep Oncol 2011, 4:464-466.
23. Dallas J.L., Jantz M.A., Lightsey J.L., Sonntag C., Kaye F.J. Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. J Thorac Oncol 2011, 1142-1143.
24. Yano S., Nakataki E., Ohtsuka S., Inayama M., Tomimoto H., Edakuni N., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005, 15:107-111.
25. Katayama T., Shimizu J., Suda K., Onozato R., Fukui T., Ito S., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4:1415-1419.
26. Masuda T., Hattori N., Hamada A., Iwamoto H., Ohshimo S., Kanehara M., et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011, 67:1465-1469.
27. Tetsumoto S., Osa A., Kijima T., Minami T., Hirata H., Takahashi R., et al. Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol 2011.
28. Endo M., Johkoh T., Kimura K., Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006, 52:135-140.
29. Mitsudomi T. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. Lancet Oncol 2011, 12:710-711.
30. Tsuboi M., Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006, 23:161-170.
31. Kuo L.C., Lin P.C., Wang K.F., Yuan M.K., Chang S.C. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol 2011, 28:79-82.